Add time:07/20/2019         Source:sciencedirect.com

IntroductionAlthough evidence supports the use of mitomycin C after transurethral bladder tumor resection in reducing recurrent disease, its adoption has been limited. Examinations of claims data may help in exploring patterns of care and barriers to use. Thus, we analyzed a contemporary population based cohort to determine recent trends in mitomycin C use in community practice urology.

We also recommend Trading Suppliers and Manufacturers of mitomycin D (cas 10169-34-3). Pls Click Website Link as below: cas 10169-34-3 suppliers